BANK VONTOBEL/PUT/NOVO NORDISK ADR B/135/0.1/19.07.24 | Market Closed - Boerse Frankfurt Warrants 18:53:18 05/07/2024 BST | ||
| 0.08 EUR | -37.98% |
|
| Current month | -1.23% | ||
| 1 month | -68.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 0.08 | -37.98% |
| 04/07/24 | 0.129 | -29.12% |
| 03/07/24 | 0.182 | +119.28% |
| 02/07/24 | 0.083 | +84.44% |
| 01/07/24 | 0.045 | -44.44% |
Real-time Boerse Frankfurt Warrants
Last update July 05, 2024 at 06:53 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD54PL |
| ISIN | DE000VD54PL7 |
| Date issued | 14/05/2024 |
| Strike | 135 $ |
| Maturity | 19/07/2024 (13 Days) |
| Parity | 10 : 1 |
| Emission price | 0.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.65 € |
|---|---|
| Lowest since issue | 0.043 € |
| Spread | 0.01 € |
| Spread % | 12.35% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Warrants
- Warrant
